Loading company
$0.67-0.7%Nov 13 close
Next earnings: November 17, 2026 · after the close
Figures through July 4, 2026, from the 10-Q filed August 18, 2026
Past performance
- 1W
- +1.5%
- 1M
- -19.1%
- 3M
- -22.1%
- 6M
- -34.0%
- 1Y
- -31.9%
- 5Y
- -92.6%
$0.67-0.7%Nov 13 close
Next earnings: November 17, 2026 · after the close
Figures through July 4, 2026, from the 10-Q filed August 18, 2026
Iridex Corp. is scheduled to report next on November 17, 2026, after the close. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending July 4, 2026, against the same quarter a year earlier.
| Measure | 3 months toJul 4, 2026 | 3 months toJun 28, 2025 | Change |
|---|---|---|---|
| Total Revenue | $12.6M | $13.6M | -7.41% |
| Profit | -$1.3M | -$994K | -27.36% |
| Profit per share | -$0.07 | -$0.06 | -16.67% |
| Free Cash Flow | $124K | -$410K | +130.24% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
“Our second quarter results were highlighted by the continued momentum in our glaucoma business and operating positive cash flows,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
Iridex Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, which include capital equipment and consumable probes for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers the therapeutic benefits of laser treatment while minimizing tissue damage, offering a safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used for the treatment of glaucoma and diabetic macular edema (DME) and other retinal diseases. Iridex products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Iridex Corp.’s Item 2.02 8-K filed August 18, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Iridex Corp. has no earnings call transcript available.